Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Cantor Fitzgerald Adjusts Johnson & Johnson PT to $215 From $200, Maintains Overweight Rating

08/18/2021 | 09:45am EST


ę MT Newswires 2021
All news about JOHNSON & JOHNSON
09:51aJohnson & Johnson's Janssen Says Phase 3b Trial of Active Psoriatic Arthritis Treatment..
MT
09:42aJOHNSON & JOHNSON : Latest Phase 3 Data for First-in-Class TREMFYA« (guselkumab) Demonstra..
PU
08:49aJohnson & Johnson's Janssen Says Psoriatic Arthritis Trial Meets Objective
DJ
12/02Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
MT
12/02Covid-19 - Mobile Vaccination Teams Deployed to Weekly Markets, Inland Regions
AQ
12/02Africans Will Get Wider Access to Vaccines in New Distribution Deal
AQ
12/01Johnson & Johnson's Janssen Lands FDA Nod for Multiple Myeloma Treatment
MT
12/01Zymeworks to Get Milestone Payment After Janssen Doses First Patient With Licensed Anti..
MT
12/01Johnson & Johnson announces significant progress towards its climate goals - 100% renew..
AQ
11/30Oklahoma Supreme Court Concludes Opioid Manufacturer J&J Cannot Be Held Liable Under St..
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 251 M - -
Net income 2021 22 542 M - -
Net Debt 2021 493 M - -
P/E ratio 2021 19,2x
Yield 2021 2,62%
Capitalization 420 B 420 B -
EV / Sales 2021 4,46x
EV / Sales 2022 4,15x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 159,38 $
Average target price 184,65 $
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.27%413 555
ROCHE HOLDING AG17.62%341 509
PFIZER, INC.44.09%297 706
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726
ABBVIE INC.8.18%206 612